Denmark Pharmaceutical Market Size Forecast 2024-2028: Key Trends and Insights

The Denmark pharmaceutical market is expected to experience significant growth, with a forecasted increase of USD 852.1 million at a compound annual growth rate (CAGR) of 3.63% between 2023 and 2028. This growth is primarily driven by substantial investments in the pharmaceutical industry, the rising demand for personalized medicines, and the country's efficient pricing and reimbursement systems.

For more details about the industry, get the PDF sample report for free

Key Market Segments

By Class Type:

• Musculoskeletal system
• Nervous system
• Respiratory system
• Others

By Distribution Channel:

• Offline
• Online

By Type:

• Prescription drugs
• OTC drugs

Regional Market Trends

Denmark:

• The market is benefiting from a strong pharmaceutical industry that focuses on personalized medicines and chronic disease treatments. Denmark’s advanced healthcare system and favorable tax policies are contributing factors to its growth.

Market Drivers

The key driver of the Denmark pharmaceutical market is the high level of investment in the sector. Denmark’s pharmaceutical industry is recognized globally, especially for its production of PDE4 inhibitors and cancer medicines. The country’s public health insurance system provides essential access to medications, and its research capabilities in therapeutic areas such as oncology, diabetes, and metabolic disorders further bolster the market.

Market Trends

An emerging trend in Denmark's pharmaceutical sector is the increasing demand for personalized medicines. These include treatments tailored to individual genetic makeups and environmental factors. Denmark's healthcare system is integrating genomic data into clinical decision-making processes, enhancing the precision of treatments. Collaborative research across universities, hospitals, and science parks is key to advancing personalized medicine.

Market Challenges

Pricing and reimbursement remain significant challenges. The Danish Medicines Agency (DKMA) plays a crucial role in determining cost-effectiveness, often linking reimbursement amounts to market prices of similar drugs. This reference pricing system creates pricing pressures for niche medications such as PDE4 inhibitors and cancer treatments. The need to balance access to advanced therapies with cost-effectiveness is an ongoing challenge for pharmaceutical companies in Denmark.

Get more details by ordering the complete report

Key Players

• AbbVie Inc.
• ALK Abello AS
• Amgen Inc.
• AstraZeneca PLC
• Baxter International Inc.
• Bayer AG
• Biogen Inc.
• DANCANN PHARMA A S
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• Ferring BV
• FUJIFILM Corp.
• Genmab AS
• H Lundbeck AS
• LEO Pharma AS
• Novo Nordisk AS
• ORIFARM GROUP A S
• ResoTher Pharma
• Takeda Pharmaceutical Co. Ltd.
• Zealand Pharma A S

Recent Developments

• SUSTAIN FORTE Trial: This landmark study, which focuses on diabetes treatment, highlights Denmark’s significant role in advancing global pharmaceutical research. The study’s outcomes may shape future diabetes care strategies and further solidify Denmark’s position in the international pharmaceutical landscape (Feb 2025).